Neutral, source-checked summary of Fifty 410’s advertised compounded GLP-1 pricing and disclosures. Its pricing is dose-tiered, so the entry price is not the maintenance-dose price.
As of 2026-06-25, GLP-1 Review Board has not established a referral relationship with Fifty 410. See our affiliate disclosure. Compensation, if any, would not affect this review or Fifty 410’s position in any list.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Medication | Entry | Mid / month-to-month | Provenance |
|---|---|---|---|
| Compounded tirzepatide | from ~$133 | ~$166 (3-mo starter) · ~$299 (m2m) reported | provider-published entry; mid/m2m secondary |
Dose-tiered: the $133 entry figure rises with dose. No subscription lock-in; multi-month plans are prepaid.
• Membership: none.
• Shipping: free overnight/2-day refrigerated, per Fifty 410 (provider-stated).
• Dose-increase: yes — dose-tiered, so price rises as you titrate up.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.
Fifty 410 names its pharmacies publicly: ProRx (a 503A pharmacy) and BPI (a 503B outsourcing facility) — more transparency than providers that don’t name a pharmacy. It states it is LegitScript-certified and does not compound or dispense itself (provider-stated). We confirmed the named pharmacies and entry pricing on its site; we did not audit batch testing.
Fifty 410 serves the United States only (provider-stated). State-by-state availability not independently confirmed.
Availability may vary by state and prescribing basis; not independently confirmed state by state. Verify directly before enrolling.
• Cancellation: no subscription lock-in; multi-month plans are paid up front (provider-stated). Verify refund terms directly.
• Named 503A/503B pharmacies (ProRx, BPI). A genuine, checkable transparency point.
• Documented clinical-need language. Its FAQ states compounded medication is provided on documented medical necessity when an FDA-approved option is not appropriate — consistent with current FDA policy framing.
• “Starting at $133.” True as an entry/starter figure; not the maintenance-dose price.
• Aggregate rating (secondary): Fifty 410 carries roughly 4.8/5 on Trustpilot across about 4,300–5,200 reviews (~89% five-star) as of mid-2026 — among the highest ratings and largest review volumes of any compounded-GLP-1 provider tracked. Most reviewers describe an easy intake, fast approval, fair multi-month pricing, and responsive portal support. We did not audit Trustpilot for review authenticity.
• Recent complaint cluster (May–June 2026): a visible run of one-star reports centers on fulfillment, not the medication concept — shipping that stretched from the advertised few-days window to 10–14+ business days, a refrigerated medication left in transit for days, an apparent shift to a two-month minimum order, and reports of under-filled vials or a lower concentration requiring a larger injection volume.
• Most serious (BBB): at least one Better Business Bureau complaint describes receiving the wrong formulation (a B12/“pink” solution the patient had not ordered) dispensed in a tinted bottle that made it hard to notice, plus a separate complaint about near-expiry dating. Fifty 410’s published responses point to its informed consent and a policy that dispensed prescription medication cannot be returned once shipped; several disputes were resolved with refunds.
• What this means for you: the aggregate is strong, but before prepaying a multi-month plan, confirm current shipping timelines and cold-chain handling, check the exact concentration and contents on the vial label on arrival, and read the refund policy — compounded prescriptions generally cannot be returned. See our cold-chain guide and pharmacy transparency checklist.
Reviews are third-party, self-reported, and not independently verified by us; they reflect individual experiences, not a controlled sample. Sources: Trustpilot and BBB, accessed 2026-06-25.
It advertises tirzepatide starting at ~$133/month, but pricing is dose-tiered and rises with dose; secondary reviews report ~$166 on a 3-month starter and ~$299 month-to-month. Verify your maintenance-dose price directly.
It names ProRx (a 503A pharmacy) and BPI (a 503B outsourcing facility) publicly.
No. Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro or Zepbound.
Update history. 2026-06-25 — initial review; entry pricing and named pharmacies verified; mid/m2m figures secondary.